Key terms
About BNTX
BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Oezlem Tuereci, and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest BNTX news
Today
12:00am ET
Analysts’ Top Healthcare Picks: Vir Biotechnology (VIR), Rocket Pharmaceuticals (RCKT)
Today
12:00am ET
Buy Rating Affirmed for BioNTech Amid Strong Financials and Promising Oncology Pipeline
Yesterday
7:51am ET
Strong Financials and Promising Oncology Pipeline Support Buy Rating for BioNTech SE
Yesterday
5:25am ET
Buy Rating for BioNTech SE on Strong H2 Revenue Outlook and Promising Oncology Pipeline
May 06
7:05pm ET
BioNTech: Hold Rating Maintained Amidst Lower Q1 Earnings and Steady Revenue Outlook
May 06
1:05pm ET
Jefferies Keeps Their Hold Rating on BioNTech SE (BNTX)
May 06
7:58am ET
BioNTech SE Faces Q1 Loss, Advances Oncology Trials
May 06
7:57am ET
BioNTech SE Reports Q1 Financial Shifts
May 06
7:05am ET
Options Volatility and Implied Earnings Moves Today, May 06, 2024
May 06
6:50am ET
BioNTech CFO: Q1 revenue reflects the ‘seasonal demand for COVID-19 vaccines’
May 06
6:48am ET
BioNTech sees FY24 CapEx EUR 400M-EUR 500M
May 06
6:47am ET
BioNTech backs FY24 revenue view EUR 2.5B-EUR 3.1B
May 06
6:46am ET
BioNTech Q1 EPS EUR (1.31) vs. EUR 2.05 last year
Apr 23
6:40am ET
Analysts Conflicted on These Healthcare Names: Cartesian Therapeutics (RNAC), Insmed (INSM) and BioNTech SE (BNTX)
Apr 17
6:20am ET
Analysts Are Bullish on These Healthcare Stocks: BioNTech SE (BNTX), Connect Biopharma Holdings (CNTB)
Apr 08
5:27pm ET
BioNTech SE Virtual AGM Scheduled for May 2024
Apr 08
7:57am ET
BioNTech Reports Promising Cancer Vaccine Data
Apr 07
4:40pm ET
BioNTech announces Phase 1 trial follow up data for mRNA-based iNeST candidate
Mar 27
7:03am ET
BioNTech price target lowered to $101 from $110 at UBS
Mar 24
9:26pm ET
Optimistic Outlook for BioNTech: A Buy Rating Amidst Vaccine Demand and Strong Oncology Pipeline
Mar 22
1:00pm ET
BioNTech price target lowered to $90 from $99 at JPMorgan
Mar 22
11:33am ET
Biotech Alert: Searches spiking for these stocks today
Mar 22
6:58am ET
BioNTech price target lowered to $90 from $115 at HSBC
Mar 22
6:21am ET
Analysts Offer Insights on Healthcare Companies: BioNTech SE (BNTX), Intuitive Surgical (ISRG) and Bolt Biotherapeutics (BOLT)
Mar 21
2:12pm ET
BioNTech price target lowered to $146 from $159 at BofA
Mar 21
10:35am ET
Hold Rating for BioNTech: Navigating Vaccine Revenue Decline and Prospective Oncology Pipeline
Mar 21
8:01am ET
Analysts Offer Insights on Healthcare Companies: BioNTech SE (BNTX), Edwards Lifesciences (EW) and Innovent Biologics (OtherIVBXF)
Mar 21
7:40am ET
Analysts Are Bullish on These Healthcare Stocks: Insulet (PODD), Annovis Bio (ANVS)
Mar 21
6:31am ET
Analysts Are Bullish on Top Healthcare Stocks: Femasys (FEMY), BioNTech SE (BNTX)
Mar 21
2:01am ET
Biontech’s Bold AI Leap: Navigating Risks and Competition in the Tech Integration Era
Mar 20
9:05pm ET
Maintaining Hold on BioNTech: A Balancing Act Between Near-Term Challenges and Long-Term Oncology Investment
Mar 20
5:55pm ET
Jefferies Keeps Their Hold Rating on BioNTech SE (BNTX)
BNTX Financials
Key terms
Ad Feedback
BNTX Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
BNTX Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
